- Home
- REVBW vs SNY Comparison
REVBW vs SNY Comparison
Compare REVBW & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVBW
- SNY
- Stock Information
- Founded
- REVBW N/A
- SNY 1994
- Country
- REVBW United States
- SNY France
- Employees
- REVBW 9
- SNY N/A
- Industry
- REVBW Biotechnology: Pharmaceutical Preparations
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- REVBW Health Care
- SNY Health Care
- Exchange
- REVBW Nasdaq
- SNY Nasdaq
- Market Cap
- REVBW N/A
- SNY N/A
- IPO Year
- REVBW 2020
- SNY N/A
- Fundamental
- Price
- REVBW N/A
- SNY $50.90
- Analyst Decision
- REVBW
- SNY Buy
- Analyst Count
- REVBW 0
- SNY 2
- Target Price
- REVBW N/A
- SNY $62.50
- AVG Volume (30 Days)
- REVBW N/A
- SNY 3.2M
- Earning Date
- REVBW N/A
- SNY 04-24-2025
- Dividend Yield
- REVBW N/A
- SNY 3.16%
- EPS Growth
- REVBW N/A
- SNY 2.94
- EPS
- REVBW N/A
- SNY 4.60
- Revenue
- REVBW N/A
- SNY $45,849,466,833.00
- Revenue This Year
- REVBW N/A
- SNY $6.91
- Revenue Next Year
- REVBW N/A
- SNY $6.60
- P/E Ratio
- REVBW N/A
- SNY $21.93
- Revenue Growth
- REVBW N/A
- SNY 7.73
- 52 Week Low
- REVBW N/A
- SNY $45.22
- 52 Week High
- REVBW N/A
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- REVBW N/A
- SNY 39.51
- Support Level
- REVBW N/A
- SNY $50.39
- Resistance Level
- REVBW N/A
- SNY $52.22
- Average True Range (ATR)
- REVBW 0.00
- SNY 1.62
- MACD
- REVBW 0.00
- SNY -0.23
- Stochastic Oscillator
- REVBW 0.00
- SNY 39.65
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).